This course has expired. You can still review the content but course credit is no longer available.
As newer therapies enter the market, treatment options and dosing strategies can be impacted by the cost of treatment, which continues to be a major factor in treatment planning. Clinicians need to consider multiple treatment options in order to properly gauge the right treatment plan for any given patient’s needs. Ophthalmologists are also only one part of the treatment paradigm for patients with diabetes; as previously described these patients tend to have other manifestations of the systemic disorder and treatment is multifactorial.
This continuing medical education activity is supported through an educational grant from Regeneron Pharmaceuticals, Inc.
Upon completion of this activity, the participant should be able to:
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education to physicians.
Credit Designation Statement
Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Policy Statement
It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty members have the following financial relationships with commercial interests:
David Eichenbaum, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Alimera Sciences; Allergan; Genentech, Inc; Ophthotech Corporation; and Regeneron Pharmaceuticals, Inc. Grant/Research Support: Alcon; Alimera Sciences; Allergan; Genentech, Inc; Ophthotech Corporation; and River Vision. Stock/Shareholder: Hemera Biosciences and US Retina.
Chirag P. Shah, MD, MPH has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support: Genentech, Inc. and Regeneron Pharmaceuticals, Inc.
Cheryl Cavanaugh, MS, Evolve Medical Education LLC; and Michelle Dalton, Writer, have no relevant commercial interests to disclose.
Rishi P. Singh, MD, Peer Reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Genentech, Inc; Regeneron Pharmaceuticals, Inc; and ThromboGenics NV. Grant/Research Support: Alcon; Genentech, Inc; Regeneron Pharmaceuticals, Inc.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC or Regeneron Pharmaceuticals Inc.